ATYR1923-C-005 EFZO CONNECT RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF EFZOFITIMOD IN PATIENTS WITH SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
aTyr Pharma, Inc.
Start Date
October 3, 2024
End Date
August 31, 2029
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
aTyr Pharma, Inc.
Start Date
October 3, 2024
End Date
August 31, 2029